bioAffinity Technologies (BIAF) Other Operating Expenses (2021 - 2026)

bioAffinity Technologies has disclosed Other Operating Expenses across 6 years of filings, most recently posting -$2.7 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 79.64% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at $962901.0 (down 72.64% YoY), while the FY2025 annual figure was $5.3 million, down 21.95% from the prior year.
• Other Operating Expenses retreated to -$2.7 million in Q1 2026, from $1.3 million in the prior quarter.
• Over the last five years, Other Operating Expenses for BIAF reached as high as $1.8 million in Q4 2024 and fell as low as -$2.7 million in Q1 2026.
• The 5-year median for Other Operating Expenses is $193600.0 (2023), against an average of $490190.0.
• Annual changes were most pronounced in 2023 — Other Operating Expenses jumped 10351.86% — and 2025, when it sank 186.3%.
• A 5-year view of Other Operating Expenses shows it stood at -$16999.0 in 2022, then jumped by 10351.86% to $1.7 million in 2023, then grew by 3.32% to $1.8 million in 2024, then decreased by 28.85% to $1.3 million in 2025, then plunged by 309.75% to -$2.7 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$2.7 million, $1.3 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.